ERBB2 and breast cancer: Several studies by Modi et al. have documented that trastuzumab deruxtecan exhibited persistent antitumor activity in a pretreated HER2-positive metastatic BC patient cohort (Tamura et al., 2019; Modi et al., 2020a).